Daniel Kavanagh, PhD, RAC
Senior Scientific Advisor, Gene Therapy, Vaccines & Biologics, WCG
Biography
Daniel Kavanagh, PhD, RAC, is the senior scientific advisor of gene therapy, vaccines, and biologics at WCG. Prior to joining WCG, he was assistant professor of medicine and Institutional Biosafety Committee vice chair at Harvard Medical School, and assistant immunologist at the Massachusetts General Hospital. He was also co-chair of a Phase 1 clinical trial of a therapeutic mRNA vaccine. He is certified in US Regulatory Affairs (RAC) by the Regulatory Affairs Professional Society.
Latest insights by Daniel
WCG Clinical | Insights
FDA Draft Guidance on Multiregional Clinical Development Programs for Oncology
Blog Posts
WCG Clinical | Insights
Elevating Site Preparedness: Trends and Strategies for 2025
Blog Posts
WCG Clinical | Insights
Four Key Elements You Need to Know About the Role of IBCs in Gene Therapy Trials
Blog Posts
WCG Clinical | Insights
As a sponsor, does my HGT clinical trial require IBC approval at all sites?
Blog Posts
WCG Clinical | Insights
Does Human Gene Transfer research at my site require IBC approval?
Blog Posts
WCG Clinical | Insights
Institutional Biosafety Committee Review for Genetically Modified Vaccines and Gene Transfer Products
Videos
WCG Clinical | Insights
NIH Launches NExTRAC to Advise on Emerging Biotechnologies
Blog Posts
WCG Clinical | Insights
Amendments to the NIH Guidelines: Effects on Human Gene Transfer Research
Blog Posts
WCG Clinical | Insights
Germline Modification for HIV Prevention is Unjustified
Blog Posts
WCG Clinical | Insights